158 related articles for article (PubMed ID: 37272562)
21. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
25. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
26. Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population-based analysis.
Yamamoto PA; Vozmediano V; Cristofoletti R; Jiang J; Schmittgen TD; de Gaitani CM; Kemp R; Sankarankutty AK; Dos Santos JS; Salgado Junior W; de Moraes NV
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38852609
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
28. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
31. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.
Feng Y; Pollock BG; Ferrell RE; Kimak MA; Reynolds CF; Bies RR
Br J Clin Pharmacol; 2006 May; 61(5):558-69. PubMed ID: 16669849
[TBL] [Abstract][Full Text] [Related]
32. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
33. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.
Oldham HG; Clarke SE
Drug Metab Dispos; 1997 Aug; 25(8):970-7. PubMed ID: 9280405
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
Sherwin CM; Saldaña SN; Bies RR; Aman MG; Vinks AA
Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
[TBL] [Abstract][Full Text] [Related]
35. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
[TBL] [Abstract][Full Text] [Related]
37. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
J Pharm Pharm Sci; 2006; 9(1):101-12. PubMed ID: 16849011
[TBL] [Abstract][Full Text] [Related]
38. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
40. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]